Enovis Corporation (ENOV)
Price:
31.37 USD
( - -0.41 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Eaton Corporation plc
VALUE SCORE:
8
2nd position
Dover Corporation
VALUE SCORE:
10
The best
Cummins Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
NEWS
Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million
globenewswire.com
2025-10-08 08:15:00Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners, a multi-family asset management firm based in Chicago, for consideration of up to $60 million in cash, consisting of an upfront payment of $45 million, and up to $15 million payable in the future upon the achievement of certain milestones.
Enovis Corporation Announces Time Change for Presentation at Baird 2025 Global Healthcare Conference
globenewswire.com
2025-09-08 16:05:00Wilmington, DE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will now present at the Baird 2025 Global Healthcare Conference at 2:35 p.m. ET on Wednesday, September 10th, 2025.
Wall Street Analysts Believe Enovis (ENOV) Could Rally 69.91%: Here's is How to Trade
zacks.com
2025-09-03 10:56:21The consensus price target hints at a 69.9% upside potential for Enovis (ENOV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Enovis (ENOV) Have the Potential to Rally 77.33% as Wall Street Analysts Expect?
zacks.com
2025-08-18 10:56:15The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Enovis to Participate in Upcoming Investor Conferences
globenewswire.com
2025-08-08 09:00:00Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
Enovis Corporation (ENOV) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-08 03:25:31Enovis Corporation (NYSE:ENOV ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Damien McDonald - CEO & Director Kyle William Rose - Vice President of Investor Relations Phillip Benjamin Berry - Senior VP & CFO Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Dane M. Reinhardt - Robert W.
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
zacks.com
2025-08-07 08:21:10Enovis (ENOV) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.62 per share a year ago.
Enovis (ENOV) Q2 Revenue Rises 7%
fool.com
2025-08-07 07:32:04Enovis (ENOV) Q2 Revenue Rises 7%
Enovis Announces Second Quarter 2025 Results
globenewswire.com
2025-08-07 06:00:00Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Enovis to Host Second Quarter 2025 Results Conference Call on August 7th
globenewswire.com
2025-07-08 16:05:00Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning.
Enovis to Participate in Upcoming Investor Conferences
globenewswire.com
2025-06-06 16:05:00Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
Orthopedic Braces & Supports Market Focused Insights 2025-2030, with Key Vendor Profiles for BREG, Bauerfeind, DeRoyals, Enovis, Ottobock, Ossur and Tynor
globenewswire.com
2025-05-26 10:46:00Key developments include Icarus Medical Innovation's Adonis Knee brace with joint-distraction technology and Enovis DJO, LLC's DonJoy ROAM knee brace. The knee braces segment holds over 35% market share, fueled by prevalent knee injuries. Hinged braces show the highest growth at 5.31%. Key developments include Icarus Medical Innovation's Adonis Knee brace with joint-distraction technology and Enovis DJO, LLC's DonJoy ROAM knee brace. The knee braces segment holds over 35% market share, fueled by prevalent knee injuries. Hinged braces show the highest growth at 5.31%.
Enovis Corporation (ENOV) Q1 2025 Earnings Call Transcript
seekingalpha.com
2025-05-11 01:46:31Enovis Corporation (NYSE:ENOV ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matthew Trerotola - Chair and Chief Executive Officer Ben Berry - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robert Marcus - JPMorgan Dane Reinhardt - Baird Danielle Antalffy - UBS Russell Yuen - William Blair Young Li - Jefferies Operator Hello, everyone, and welcome to the Enovis Corporation Q1 2025 Results Call. My name is Ezra, and I will be your coordinator today.
Enovis (ENOV) Q1 Earnings and Revenues Surpass Estimates
zacks.com
2025-05-08 08:30:41Enovis (ENOV) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.50 per share a year ago.
Enovis Announces First Quarter 2025 Results
globenewswire.com
2025-05-08 06:00:00Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12 th , 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
No data to display
Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million
globenewswire.com
2025-10-08 08:15:00Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners, a multi-family asset management firm based in Chicago, for consideration of up to $60 million in cash, consisting of an upfront payment of $45 million, and up to $15 million payable in the future upon the achievement of certain milestones.
Enovis Corporation Announces Time Change for Presentation at Baird 2025 Global Healthcare Conference
globenewswire.com
2025-09-08 16:05:00Wilmington, DE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will now present at the Baird 2025 Global Healthcare Conference at 2:35 p.m. ET on Wednesday, September 10th, 2025.
Wall Street Analysts Believe Enovis (ENOV) Could Rally 69.91%: Here's is How to Trade
zacks.com
2025-09-03 10:56:21The consensus price target hints at a 69.9% upside potential for Enovis (ENOV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Enovis (ENOV) Have the Potential to Rally 77.33% as Wall Street Analysts Expect?
zacks.com
2025-08-18 10:56:15The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Enovis to Participate in Upcoming Investor Conferences
globenewswire.com
2025-08-08 09:00:00Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
Enovis Corporation (ENOV) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-08 03:25:31Enovis Corporation (NYSE:ENOV ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Damien McDonald - CEO & Director Kyle William Rose - Vice President of Investor Relations Phillip Benjamin Berry - Senior VP & CFO Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Dane M. Reinhardt - Robert W.
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
zacks.com
2025-08-07 08:21:10Enovis (ENOV) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.62 per share a year ago.
Enovis (ENOV) Q2 Revenue Rises 7%
fool.com
2025-08-07 07:32:04Enovis (ENOV) Q2 Revenue Rises 7%
Enovis Announces Second Quarter 2025 Results
globenewswire.com
2025-08-07 06:00:00Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Enovis to Host Second Quarter 2025 Results Conference Call on August 7th
globenewswire.com
2025-07-08 16:05:00Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning.
Enovis to Participate in Upcoming Investor Conferences
globenewswire.com
2025-06-06 16:05:00Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
Orthopedic Braces & Supports Market Focused Insights 2025-2030, with Key Vendor Profiles for BREG, Bauerfeind, DeRoyals, Enovis, Ottobock, Ossur and Tynor
globenewswire.com
2025-05-26 10:46:00Key developments include Icarus Medical Innovation's Adonis Knee brace with joint-distraction technology and Enovis DJO, LLC's DonJoy ROAM knee brace. The knee braces segment holds over 35% market share, fueled by prevalent knee injuries. Hinged braces show the highest growth at 5.31%. Key developments include Icarus Medical Innovation's Adonis Knee brace with joint-distraction technology and Enovis DJO, LLC's DonJoy ROAM knee brace. The knee braces segment holds over 35% market share, fueled by prevalent knee injuries. Hinged braces show the highest growth at 5.31%.
Enovis Corporation (ENOV) Q1 2025 Earnings Call Transcript
seekingalpha.com
2025-05-11 01:46:31Enovis Corporation (NYSE:ENOV ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matthew Trerotola - Chair and Chief Executive Officer Ben Berry - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robert Marcus - JPMorgan Dane Reinhardt - Baird Danielle Antalffy - UBS Russell Yuen - William Blair Young Li - Jefferies Operator Hello, everyone, and welcome to the Enovis Corporation Q1 2025 Results Call. My name is Ezra, and I will be your coordinator today.
Enovis (ENOV) Q1 Earnings and Revenues Surpass Estimates
zacks.com
2025-05-08 08:30:41Enovis (ENOV) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.50 per share a year ago.
Enovis Announces First Quarter 2025 Results
globenewswire.com
2025-05-08 06:00:00Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12 th , 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.